Wave of optimism sweeps France as World Cup unites nation
Big Sam blames Harry Kane for Croatia defeat
Jose Mourinho baffled by Ivan Perisic's refusal to join
Pakistan begin ODI series against Zimbabwe as favourites
Federation Internationale de Football Association tells broadcasters stop zooming in on women in World Cup crowds
Sage Therapeutics Reports Successful Depression Drug Study
08 December 2017, 10:22 | Henrietta Morgan
SAGE Therapeutics Inc
Sage Therapeutics shares are once again rocketing up this morning, this time based on positive results from a small Phase II study of an oral version of their depression therapy. (NASDAQ:SAGE). Denver Advisors Ltd Liability Com has invested 0.02% of its portfolio in Sage Therapeutics, Inc. Dupont Cap accumulated 13,528 shares.
Long one of the most volatile stocks in biotech, Sage says that SAGE-217 clearly hit the goal post for statistical significance in major depressive disorder, achieving a 64% success rate in achieving clinical remission on a commonly used score for depression against 23% on a placebo.
Trading stocks at an all time highs is usually a winning strategy. State of Wisconsin Investment Board acquired a new position in Sage Therapeutics during the second quarter valued at approximately $1,991,000.
Lookout the Analyst's Suggestions:: Merck & Co., Inc. (MRK)
Twelve investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company's stock. Private Management invested in 263,602 shares. 12,163 were accumulated by Crestwood Advisors Limited Liability Company.
SAGE has been the subject of several other research reports. J P Morgan Chase & Co lowered their price target on shares of Sage Therapeutics from $99.00 to $85.00 and set an "overweight" rating for the company in a research report on Tuesday, September 12th. (NASDAQ:SAGE). Jabre Sa has invested 0.03% of its portfolio in Sage Therapeutics, Inc. ValuEngine upgraded Protagonist Therapeutics from a "sell" rating to a "hold" rating in a research note on Monday, August 28th. About 6.61 million shares traded or 676.95% up from the average. Tightening the gaze, stock performance for the last 5 trading days is -2.39%. The company reported ($0.29) earnings per share for the quarter, topping analysts' consensus estimates of ($0.69) by $0.40. Sage Therapeutics has a 12 month low of $44.55 and a 12 month high of $100.50. Therefore 88% are positive.
In the grander scheme, "While some investors may want to take profits (with stock up 75% before the open), we think the long-range prospects for SAGE are positive and maintain our BUY rating". From the opening price, the stock has seen a change of -0.40% recently clocking in with a price of $160.54. SAGE Therapeutics had 45 analyst reports since September 3, 2015 according to SRatingsIntel. Cowen & Co maintained the stock with "Buy" rating in Thursday, November 9 report. Bank of America maintained the shares of SAGE in report on Thursday, November 16 with "Buy" rating. The firm earned "Buy" rating on Tuesday, September 12 by Leerink Swann. Stifel Nicolaus maintained Sage Therapeutics, Inc. (NASDAQ:SAGE) on Wednesday, June 29 with "Outperform" rating. The firm has "Buy" rating given on Tuesday, September 12 by Canaccord Genuity. As per Thursday, December 7, the company rating was maintained by Leerink Swann.
SAGE Therapeutics Inc (NASDAQ:SAGE) is roaring up almost 77% through the market ceiling after a massively successful Phase 2 read-out in major depressive disorder (MDD), earning a new shot of confidence from an already positive bull on the Street.
Praising the depression drug's safety profile, the analyst elaborates: "Safety clean, highly encouraging SAGE-217 showed a clean safety profile with adverse events consistent with prior studies, including headache, dizziness, nausea, and somnolence". (NASDAQ:SAGE) were released by: Schaeffersresearch.com and their article: "SAGE Therapeutics Options Traders Don't Buy Depression Drug Breakout" published on December 07, 2017 as well as Nasdaq.com's news article titled: "Mid-Day Market Update: Duluth Holdings Drops Following Q3 Results; SAGE ..." with publication date: December 07, 2017. Hershey Trust Co. bought a new position in shares of Sage Therapeutics in the 3rd quarter worth about $118,000. The company has market cap of $22.06 million. "There has been little innovation in the discovery and development of treatments for depression in the last two decades", Sage's chief executive, Jeff Jonas, said in a statement.
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of autoimmune-inflammatory, oncological, and liver diseases, as well as sexual dysfunction. It now has negative earnings.
Competing Reviews of Woody Allen's Wonder Wheel
Humpty ( Jim Belushi ), Carolina's father and Ginny's husband, struggles with his alcohol abuse and the return of his daughter. It also shows how things in life can change like the seasons but that they also often stay exactly the same.
Sango, PDP chieftain kidnapped
We have no communication with the six occupants of the vehicle including the abductors and no ransom has been made. A family member, Mr Jonathan Mapis, who spoke on the issue, said that the victims were abducted "around 5.30 p.m".
Philippe Coutinho forward admits to Barcelona interest
Coutinho's hat-trick was his first for Liverpool and the Brazilian insists the win over Spartak will live long in his memory. Mundo Deportivo reported on Thursday morning that a deal is already in place for the playmaker to sign a five-year contract.